Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | Safety, efficacy and tolerability of ide-cel in the real-world

Surbhi Sidana • 27 Aug 2022
IMS 2022
Multiple Myeloma CAR-T Idecabtagene vicleucel
KarMMa

Surbhi Sidana, MD, Mayo Clinic, Stanford, CA, comments on the results of a study investigating the real-world safety, efficacy, and tolerability of idecabtagene vicleucel (ide-cel) in patients with relapsed/refractory (R/R) multiple myeloma. Overall, it was found that ide-cel was very effective in the real world, and toxicity rates were comparable to what was observed in the KarMMa trial (NCT03361748). This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Surbhi Sidana

1:29
Managing toxicities associated with immunotherapy in multiple myeloma
Surbhi Sidana • 8 Dec 2023
1:43
Ide-cel therapy for multiple myeloma with renal impairment
Surbhi Sidana • 8 Dec 2023
3:09
An overview of the toxicities associated with immunotherapy in multiple myeloma
Surbhi Sidana • 8 Dec 2023
1:59
Real-world outcomes of ide-cel in heavily pre-treated R/R MM
Surbhi Sidana • 8 Dec 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals